Peptide Policy: ISO Processing Referrals

What does the new peptide announcement actually cover?

An October 2026 HHS notice describes a draft enforcement-discretion policy concerning certain peptide bulk substances used in section 503A compounding. It also describes an interim enforcement position while rulemaking continues. That gives an ISO a reason to check whether a referral's facts merit another conversation, not a basis to announce that peptide businesses now qualify for processing.

The accompanying policy concerns specified circumstances for state-licensed pharmacies, federal facilities and licensed physicians. Conditions address substances, sourcing and compounding. This is not a final 503A bulks-list rule or a payment-acceptance decision. Have the merchant's qualified advisers assess the policy against its actual activity; this guide addresses referral preparation, not clinical or legal eligibility.

Sources: HHS / Federal Register: HHS notice of availability, document 2026-22192; HHS: HHS peptide compounding enforcement policy; FDA: USApeptide.com warning letter

Why should an ISO separate three business models?

MerchantBridge's referral recommendation is to begin with the transaction, not the ingredient name. A laboratory supplier selling research materials, a clinic charging for professional care and a pharmacy dispensing a compounded product describe different activities. A news story mentioning peptides does not explain which of those activities an applicant performs.

Ask the prospective merchant to identify its role in one plain sentence and give an example of what appears in the cart or on the invoice. Then compare that description with the public website. If the answer changes depending on the page being discussed, record the inconsistency as a question to resolve, not as a reason to choose a more convenient category.

What should the referral brief say after a policy change?

Use a dated change note alongside the ordinary business brief. The useful question is not just whether a rule has changed; it is whether the merchant's actual activity, evidence or proposed payment arrangement has changed. Keep confirmed facts separate from the merchant's interpretation and from questions awaiting partner review.

A filled-in hypothetical change note could read: US research supplier; online sales of RUO materials; no change to catalog, customer controls or business role since the last review. Trigger: October HHS compounding announcement. Question: does any available partner wish to reassess this research-supply activity on its own facts? This describes a discussion request, not a switch into the pharmacy category or a reported MerchantBridge placement.

• Source: the official notice or policy, date checked and any stated effective date or interim status.
• Merchant role: research supplier, clinic, pharmacy or another clearly described business.
• Activity: actual products or services, intended customers and where transactions occur.
• Change: what is different since the previous review, with evidence rather than an optimistic summary.
• Open question: the precise issue the potential payment partner needs to assess.

Does an RUO disclaimer settle the review?

No. In its February 2025 USApeptide.com warning letter, FDA explained that website evidence indicated intended human drug use despite research-use disclaimers. That letter concerns a particular recipient and its products; it is not a finding about every research seller. It does demonstrate why a disclaimer should not be treated as the whole factual description.

For referral preparation, preserve the actual product and marketing context. Ask the merchant to resolve contradictory descriptions with its advisers and provide accurate information. Do not suggest hiding pages, changing a label to bypass review or treating pharmacy-related news as permission for consumer use of RUO products.

What can you responsibly tell the merchant now?

A useful response is: We can revisit the available processing options using your current business profile and the official development you flagged. Please confirm what has changed since the last review. That sets a concrete next step without quoting an approval probability or promising a launch date. An earlier decline does not establish how every other partner will assess the opportunity.

Ask what outcome the merchant needs: a first processing relationship, a review of a changed operating model or clarification before introducing a new product line. A precise objective makes the conversation useful without committing anyone to a placement. Record who will provide any additional evidence and who is authorized to communicate with the merchant.

How should the ISO start the conversation?

Start with your own contact details and a concise business summary. Include the official development being discussed, the merchant's role and the unresolved referral question. A first inquiry should not contain patient records, payment-card information or a large package of sensitive documents.

MerchantBridge brings relationships across full-risk ISO, acquiring-bank and international acquiring channels to the discussion. If your current channels cannot consider the opportunity, we can review the business summary and explore available alternatives. Acceptance and referral terms remain case-specific. Recheck the official policy before relying on this guide later, particularly if the merchant changes its activity.